Table 2 p53 expression in relation to clinical parameters and HPV status in Kazakh patients with ESCC
Clinical properties | Total | p53 expression (n/%) | ||
|---|---|---|---|---|
Negative (%) | Positive (%) | P value | ||
Gender | ||||
 Male | 106 | 10(52.6 %) | 96(66.7 %) | 0.228 |
 Female | 57 | 9(47.4 %) | 48(33.3 %) | |
Age (mean) | ||||
  < 58 | 82 | 7(36.8 %) | 75(53.6 %) | 0.171 |
  ≥ 58 | 77 | 12(63.2 %) | 65(46.4 %) | |
Histopathological gradea | ||||
 Well | 40 | 8(42.1 %) | 32(22.9 %) | 0.070 |
 Moderate | 98 | 8(42.1 %) | 91(65.0 %) | |
 Poor | 20 | 3(15.8 %) | 17(12.1 %) | |
Invasion depth | ||||
 T1-T2 | 76 | 8(47.1 %) | 68(51.1 %) | 0.752 |
 T3-T4 | 74 | 9(52.9 %) | 65(48.9 %) | |
Lymphatic invasion | ||||
 N0 | 68 | 6(33.3 %) | 62(49.2 %) | 0.207 |
 N1-N3 | 76 | 12(66.7 %) | 64(50.8 %) | |
TNM Staging | ||||
 I/II | 79 | 9(60.0 %) | 70(64.2 %) | 0.750 |
 III/IV | 45 | 6(40.0 %) | 39(35.8 %) | |
HPV infection | ||||
 Negative | 67 | 4(28.6 %) | 63(57.8 %) | 0.039 |
 Positive | 56 | 10(71.4 %) | 46(42.2 %) | |